GregoryMarkEnnsMD

Medical Genetics • Palo Alto, CA

Clinical Biochemical Genetics, Clinical Genetics

Associate Professor, Pediatrics - Medical Genetics, Stanford University Medical Center

Join to view full profile

Dr. Enns is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Enns' full profile

Already have an account?

Office
725 Welch Rd
Palo Alto, CA 94304
Phone+1 650-497-8000

Education & Training

University of California (San Francisco)Residency, Medical Genetics and Genomics, 1995 - 1998
Children's Hospital Los AngelesResidency, Pediatrics, 1991 - 1995
University of Glasgow Faculty of MedicineClass of 1990

Certifications & Licensure

OR State Medical License 2011 - Present
CA State Medical License 1993 - 2027
HI State Medical License 2003 - 2026
FL State Medical License 2012 - 2020
American Board of Medical Genetics and Genomics Clinical Biochemical Genetics
American Board of Medical Genetics and Genomics Clinical Genetics and Genomics

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Fellow (FAAP) American Academy of Pediatrics

Clinical Trials

EPI-743 for Mitochondrial Respiratory Chain Diseases
No longer available
Long-term Outcome of N-Carbamylglutamate Treatment in Propionic Acidemia and Methylmalonic Acidemia Start of enrollment: 2012 Sep 01
Terminated
Phase 2
Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia Start of enrollment: 2012 Sep 01
Completed
Phase 2
The Effects of Sapropterin Dihydrochloride Supplementation on in Vivo Redox Status in Patients With Classical PKU Start of enrollment: 2012 Jul 01
Withdrawn
North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) Start of enrollment: 2010 Dec 01
Recruiting
Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease Start of enrollment: 2014 May 01
Completed
Phase 2
Phase 2 Study of EPI-743 in Children With Pearson Syndrome Start of enrollment: 2014 Aug 31
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

Newborn Screening for X-Linked Adrenoleukodystrophy (X-ALD): Biochemical, Molecular, and Clinical Characteristics of Other Genetic Conditions.
Carlos F Mares Beltran, Christina G Tise, Rebekah Barrick, Annie D Niehaus, Rebecca Sponberg
Genes. 2024-06-26
5 citations
Efficacy and safety of pegzilarginase in arginase 1 deficiency (PEACE): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trial.
Rossana Sanchez Russo, Serena Gasperini, Gillian Bubb, Linda Neuman, Leslie S Sloan
Eclinicalmedicine. 2024-02-01
Specifications of the ACMG/AMP guidelines for ACADVL variant interpretation.
May Flowers, Alexa Dickson, Marcus J Miller, Elaine Spector, Gregory Mark Enns
Molecular Genetics and Metabolism. 2023-11-01

Press Mentions

M6P Therapeutics to Host Key Opinion Leader Webinar on Lysosomal Storage DisordersJuly 19th, 2021
M6P Therapeutics Announces Formation of Distinguished, Experienced Scientific Advisory BoardFebruary 3rd, 2021
The Bay Area's Top Doctors of 2019January 17th, 2019
Join now to see all

Professional Memberships

American Academy of Pediatrics - AAP
Fellow